ClinicalTrials.gg
Active, not recruitingNCT07137585Updated Sep 29, 2026

A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity

A Phase 1 interventional study of Placebo and RO7204239 in Type 2 Diabetes Mellitus, Obesity and Overweight, sponsored by Hoffmann-La Roche. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche — 7 open to participants now, 8 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Hoffmann-La Roche.

Planned enrollment
61st of 73
30 · median 196
Started
2025
with 2 others
Phase 1
19 of 73
none open now
Registered
68th of 73
by date

Among the 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche, this one is the 61st largest by planned enrollment, is one of 3 that started in 2025, is one of 19 in phase 1, and was the 68th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the effect of RO7204239 on insulin sensitivity versus placebo in participants with T2DM and obesity or overweight.

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with T2DM for at least 6 months, treated with diet, exercise and/or metformin alone or in combination with either dipeptidyl peptidase 4 (DPP-4) inhibitor or sodium-glucose co-transporter 2 (SGLT2) at stable dose for the last 3 months prior to study entry and with a between ≤ 6.5% and ≤ 10%
  • (BMI) within the range of 27.0 to 45.0 kilogram per meter square (kg/m2)
  • Stable body weight for the 3 months prior to screening
  • Participants on lipid-lowering or antihypertensive drugs must be on stable doses for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus (DM), known latent diabetes in adults, or people with an episode of ketoacidosis or hyperosmolar state requiring hospitalisation in 6 months prior to screening
  • Active proliferative diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy requiring acute treatment
  • Uncontrolled comorbid conditions commonly associated with diabetes (for example, hypertension, hyperlipidaemia)
  • Severe hypoglycaemia within 6 months prior to screening visit
  • Current autonomic neuropathy as evidenced by neuropathic urinary retention, resting tachycardia, orthostatic hypotension, or diabetic diarrhea
  • Have evidence of a significant, uncontrolled endocrine abnormality (e.g., thyrotoxicosis and adrenal crises)
  • Are currently taking a central nervous system stimulant (e.g., Ritalin-SR), with the exception of caffeinated beverage
  • Have a known allergy, , or intolerance to any component of the study treatment (i.e., RO7204239 / placebo) formulation
  • Blood donation of more than 500 milliliters (mL) within the past 3 months or blood transfusion or severe blood loss within 3 months prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Placebo

    Participants will receive RO7204239 matching placebo, every 4 weeks (Q4W), as a subcutaneous (SC) injection for 24 weeks.

    Drug: Placebo

  • Experimental
    RO7204239

    Participants will receive RO7204239, Q4W, as a SC injection for 24 weeks.

    Drug: RO7204239

Interventions

  • DrugPlacebo

    RO7204239 matching placebo will be administered as per the schedule specified in the treatment arm.

  • RO7204239 will be administered as per the schedule specified in the treatment arm.

    Also known as: GYM329

06

What researchers measure

Primary outcomes

  1. Change From Baseline in M-value in a Hyperinsulinemic Euglycemic Glucose Clamp (HEC) at Week 24

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12 and 24

    Time frame: Baseline, Week 12, Week 24

  2. Change From Baseline in Glucose Metabolism Assessed Using Fasting Glucose Test at Weeks 12 and 24

    Time frame: Baseline, Week 12, Week 24

  3. Change From Baseline in Glucose Metabolism Assessed Using Insulin Test at Weeks 12 and 24

    Time frame: Baseline, Week 12, Week 24

  4. Change From Baseline in Glucose Metabolism Assessed Using C-peptide Test at Weeks 12 and 24

    Time frame: Baseline, Week 12, Week 24

  5. Change From Baseline in Blood Lipid Profiles at Weeks 12 and 24

    Time frame: Baseline, Week 12, Week 24

  6. Change From Baseline in Body Weight at Weeks 12 and 24

    Time frame: Baseline, Week 12, Week 24

  7. Change From Baseline in Waist Circumference at Weeks 12 and 24

    Time frame: Baseline, Week 12, Week 24

  8. Change From Baseline in Waist to Height Ratio at Weeks 12 and 24

    Time frame: Baseline, Week 12, Week 24

  9. Change From Baseline in Total Lean Tissue Volume and Total Adipose Tissue Volume From Abdominal Magnetic Resonance Imaging (MRI) at Weeks 12 and 24

    Time frame: Baseline, Week 12, Week 24

  10. Change From Baseline in Muscle Volume From Thigh Muscle MRI at Weeks 12 and 24

    Time frame: Baseline, Week 12, Week 24

  11. Change From Baseline in Muscle Fat Infiltration From Thigh Muscle MRI at Weeks 12 and 24

    Time frame: Baseline, Week 12, Week 24

  12. Number of Participants With Adverse Events (AEs)

    Time frame: Up to Week 48

  13. Number of Participants With Local and Systemic Injection Reactions

    Time frame: Up to Week 48

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung
    Homburg, Saarland 66421, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Sep 2026, 11 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 11 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2025
First posted
Aug 22, 2025
StartActual
Sep 30, 2025
Primary completionActual
Sep 14, 2026
CompletionEst.
Feb 28, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and date precision
1 update, last Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07137585
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Sep 30, 2025
Primary completion
Sep 14, 2026
Completion
Feb 28, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emugrobart

Start the discussion